Lloyd Payne Joins Kineticos as Venture Partner for Kineticos AMR Accelerator Fund I (KAMRA I)
Raleigh, North Carolina – January 31st, 2025 – Kineticos Life Sciences is pleased to announce that Lloyd Payne, D.Phil., has joined as a Venture Partner for the Kineticos AMR Accelerator Fund I (KAMRA I). Dr. Payne, a seasoned biopharmaceutical executive with over 25 years of experience in drug discovery and development, will play a key role in advancing Kineticos’ vision of A World Without Antimicrobial ResistanceTM.
Dr. Payne currently serves as Chief Executive Officer of a newly established spin-out from a U.S. university, founded through the Kineticos Foundry program, which is dedicated to developing a novel class of antibacterials. His extensive background in infectious diseases, coupled with a track record of leadership in early-stage biotechnology companies, makes him a valuable addition to KAMRA I.
“We are thrilled to welcome Lloyd to the KAMRA team as we work toward a world free of AMR,” said Shailesh Maingi, Founder and Managing Partner of Kineticos. “With over 25 years of experience, Lloyd brings invaluable expertise that will enhance our efforts to invest in and support companies developing innovative technologies to combat these devastating diseases. We look forward to collaborating closely with Lloyd, leveraging his insights and leadership through board and executive-level participation to strengthen our portfolio.”
Prior to joining Kineticos, Dr. Payne served as CEO of a U.S. biotech company, leading the development of a platform that leverages artificial intelligence and machine learning to discover and optimize new classes of antibacterials. Earlier in his career, he was the founding CEO of Euprotec, a specialty anti-infectives CRO, which he successfully grew before its acquisition by Evotec in 2014. Following the acquisition, he took on the role of EVP, Global Head of Anti-infectives at Evotec.
With a background in medicinal chemistry, Dr. Payne has contributed to a broad range of therapeutic programs across oncology, inflammation, and infectious diseases. He also serves as an advisor to leading sector-specific anti-infective investment funds, including the AMR Action Fund and the Novo Foundation REPAIR Impact Fund, and provides scientific guidance to several biotech companies in the AMR and antibiotics space.
“I am delighted to join Kineticos Life Sciences and contribute to advancing its mission of building companies delivering innovative and effective anti-infective therapies to patients,” said Dr. Payne. “I look forward to working with the team and KAMRA I portfolio companies to help turn the tide against one of the most significant global health challenges of our time.”
KAMRA I is dedicated to combating antimicrobial resistance (AMR) by investing in and supporting companies that are developing groundbreaking solutions to address this critical public health issue. The fund’s unique approach combines deep sector expertise, strategic partnerships, and hands-on company-building to drive innovation in the anti-infectives space.
About Kineticos
Kineticos Life Sciences (Kineticos) envisions a world without antimicrobial resistance, cancer, and rare and neurodegenerative diseases. We are entrepreneurs helping entrepreneurs build companies to improve patient outcomes. Kineticos leverages our expertise, network, ecosystem, and capital to provide the most relevant insights and recommendations for our portfolio companies, building value every step of the way. Kineticos began investing in 2019 and through its investment vehicles has invested more than $75M across 13 companies, as of September 30, 2024.
Contact: investorrelations@kineticos.com
www.kineticos.com
Linkedin:@Kineticos